EGFR (N771_P772insN)

EGFR · Variant type: indel · HGVS: p.N771_P772insN

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Canertinib	99.1%	0.9%	96.49
2	Mobocertinib	98.8%	1.2%	97.22
3	Lazertinib	98.3%	1.7%	97.47
4	Neratinib	97.7%	2.3%	93.18
5	Pralsetinib	97.3%	2.7%	93.43
6	Erlotinib	97.0%	3.0%	99.75
7	Vandetanib	93.8%	6.3%	95.74
8	Pacritinib	70.8%	29.2%	88.64
9	Alpelisib	58.1%	41.9%	97.22
10	Pemigatinib	42.6%	57.4%	98.23
11	Gilteritinib	37.4%	62.6%	88.97
12	Zanubrutinib	25.5%	74.5%	98.24
13	Defactinib	25.2%	74.8%	92.68
14	Capmatinib	13.4%	86.6%	99.75
15	Pirtobrutinib	11.0%	89.0%	99.49
16	Tenalisib	8.4%	91.6%	97.98
17	Infigratinib	7.8%	92.2%	98.24
18	Selumetinib	7.4%	92.6%	100.00
19	Tucatinib	6.9%	93.1%	99.75
20	Apatinib	6.3%	93.7%	97.73
21	Leniolisib	5.9%	94.1%	100.00
22	Remibrutinib	5.8%	94.2%	99.50
23	Paxalisib	5.5%	94.5%	99.75
24	Idelalisib	5.1%	94.9%	100.00
25	Gedatolisib	3.4%	96.6%	99.75

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Canertinib	99.1%	98.4%	+0.6%
Mobocertinib	98.8%	100.0%	-1.2%
Lazertinib	98.3%	100.0%	-1.7%
Neratinib	97.7%	100.0%	-2.3%
Pralsetinib	97.3%	99.1%	-1.8%
Erlotinib	97.0%	99.4%	-2.5%
Vandetanib	93.8%	99.3%	-5.6%
Pacritinib	70.8%	—	—
Alpelisib	58.1%	—	—
Pemigatinib	42.6%	—	—
Gilteritinib	37.4%	91.0%	-53.6%
Zanubrutinib	25.5%	88.2%	-62.6%
Defactinib	25.2%	94.6%	-69.4%
Capmatinib	13.4%	—	—
Pirtobrutinib	11.0%	—	—
Tenalisib	8.4%	—	—
Infigratinib	7.8%	—	—
Selumetinib	7.4%	—	—
Tucatinib	6.9%	—	—
Apatinib	6.3%	—	—
Leniolisib	5.9%	—	—
Remibrutinib	5.8%	—	—
Paxalisib	5.5%	—	—
Idelalisib	5.1%	—	—
Gedatolisib	3.4%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.3ms